Novel iontophoretic administration method for local therapy of breast cancer

作者：Komuro Masahito^*; Suzuki Kenichi; Kanebako Makoto; Kawahara Takashi; Otoi Takeshige; Kitazato Kenji; Inagi Toshio; Makino Kimiko; Toi Masakazu; Terada Hiroshi

来源：Journal of Controlled Release, 2013, 168(3): 298-306.

DOI：10.1016/j.jconrel.2013.03.021

• Drug delivery system
• Ductal carcinoma in situ
• Miproxifen
• Iontophoresis
• Milk duct
• Primary breast cancer

Ductal drug therapy is a novel therapeutic approach for primary breast cancers, particularly those involving ductal carcinoma in situ lesions. Total or partial mastectomy with or without radiotherapy is the standard local therapy for primary breast cancer. Here, we propose a novel drug administration method for ductal drug therapy based on a drug delivery system (DDS) for primary breast cancer. This DDS was designed to deliver miproxifen phosphate (TAT-59), an antiestrogen drug, to ductal lesions via the milk duct, where carcinomas originate, more efficiently than systemic administration, using an iontophoretic technique applied to the nipple (IP administration). Autoradiography imaging confirmed that TAT-59 was directly delivered to the milk duct using IP administration. The plasma concentrations of TAT-59 and its active metabolite DP-TAT-59 were quite low with IP administration. The area under the curve value of DP-TAT-59 in the mammary tissue was approximately 3 times higher with IP administration than with oral administration, at a 6-fold lower dose, indicating higher availability of the drug delivered via DDS than via systemic administration. The low plasma concentrations would limit adverse effects to minor ones. These characteristics show that this DDS is suitable for the delivery of active DP-TAT-59 to ductal lesions.

• 出版日期2013-6-28